Literature DB >> 16922815

Pre-eclampsia: contribution of maternal constitutional factors and the consequences for cardiovascular health.

Anne Barden1.   

Abstract

1. Pre-eclampsia is a serious complication of pregnancy that is potentially life threatening for both the mother and baby. It encompasses a number of abnormalities that may be present in other clinical conditions. 2. A placenta is essential for the development of pre-eclampsia and can be important in the pathogenesis of pre-eclampsia. Normal pregnancy is associated with remodelling of the maternal spiral arteries, which deliver blood to the placental villous space. Remodelling involves invasion by placental cytotrophoblasts that cause the maternal spiral arteries to lose their smooth muscle and become capacitance vessels; this process, known as placentation, is complete by 20 weeks of pregnancy. Poor placentation is associated with small-for-gestational-age fetuses and some cases of pre-eclampsia. It is thought that poor placentation can result in a hypoxic placenta that releases 'toxic substances' into the maternal circulation, contributing to the maternal syndrome. A number of candidate 'toxic substances' have been proposed, but none is universally raised in pre-eclampsia. 3. Although the placenta is necessary for the development of pre-eclampsia, the extent to which placental abnormalities contribute to the condition varies. It is becoming apparent that maternal constitutional factors may also be important in this syndrome. Underlying hypertension, diabetes and obesity strongly predispose to pre-eclampsia. However, a continuum of risk may exist for blood pressure, bodyweight, glucose and lipids, which, in combination with each other and some degree of placental abnormalities, may lead to the development of pre-eclampsia. 4. The present review will focus on the maternal constitutional factors that define the metabolic syndrome and examine their contribution to pre-eclampsia and the long-term consequences for cardiovascular health.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16922815     DOI: 10.1111/j.1440-1681.2006.04448.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  10 in total

1.  eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype.

Authors:  Feng Li; John R Hagaman; Hyung-Suk Kim; Nobuyo Maeda; J Charles Jennette; James E Faber; S Ananth Karumanchi; Oliver Smithies; Nobuyuki Takahashi
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

2.  Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice.

Authors:  Athar H Siddiqui; Roxanna A Irani; Yujin Zhang; Yingbo Dai; Sean C Blackwell; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2010-12-23       Impact factor: 2.689

3.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

4.  Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome.

Authors:  Kedra Wallace; Rachael Morris; Patrick B Kyle; Denise Cornelius; Marie Darby; Jeremy Scott; Janae Moseley; Krystal Chatman; Babbette Lamarca
Journal:  Hypertens Pregnancy       Date:  2014-02       Impact factor: 2.108

5.  The pathophysiology of obesity and its clinical manifestations.

Authors:  Richard N Redinger
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

6.  Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study).

Authors:  Denise H J Delahaije; Sander M J van Kuijk; Carmen D Dirksen; Simone J S Sep; Louis L Peeters; Marc E Spaanderman; Hein W Bruinse; Laura D de Wit-Zuurendonk; Joris A M van der Post; Johannes J Duvekot; Jim van Eyck; Mariëlle G van Pampus; Mark A B H M van der Hoeven; Luc J Smits
Journal:  BMC Pregnancy Childbirth       Date:  2010-10-11       Impact factor: 3.007

Review 7.  Protein nitration in placenta - functional significance.

Authors:  R P Webster; V H J Roberts; L Myatt
Journal:  Placenta       Date:  2008-10-11       Impact factor: 3.481

8.  Estrogen-related receptor γ serves a role in blood pressure homeostasis during pregnancy.

Authors:  Yanmin Luo; Premlata Kumar; Chien-Cheng Chen; Jordan Latham; Lei Wang; Carmen Tudela; James M Alexander; John M Shelton; Leslie McKown; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2014-04-11

9.  Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus.

Authors:  Meryam Sugulle; Ralf Dechend; Florian Herse; M Susanne Weedon-Fekjaer; Guro M Johnsen; K Bridget Brosnihan; Lauren Anton; Friedrich C Luft; Kai C Wollert; Tibor Kempf; Anne Cathrine Staff
Journal:  Hypertension       Date:  2009-05-26       Impact factor: 10.190

10.  Involvement of Receptor for Advanced Glycation Endproducts in Hypertensive Disorders of Pregnancy.

Authors:  Juria Akasaka; Katsuhiko Naruse; Toshiyuki Sado; Tomoko Uchiyama; Mai Makino; Akiyo Yamauchi; Hiroyo Ota; Sumiyo Sakuramoto-Tsuchida; Asako Itaya-Hironaka; Shin Takasawa; Hiroshi Kobayashi
Journal:  Int J Mol Sci       Date:  2019-11-01       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.